Want to see HK:2607 full AI Analyst Report?
Shanghai Pharmaceuticals Holding Co (2607) Ratios
Shanghai Pharmaceuticals Holding Co Ratios
HK:2607's free cash flow for Q3 2026 was $650.84M. For the 2026 fiscal year, HK:2607's free cash flow was decreased by $-519.51M and operating cash flow was $1.17B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.33 | 1.36 | 1.33 | 1.35 | 1.27 |
| Quick Ratio | 1.00 | 1.05 | 1.03 | 1.04 | 0.97 |
| Cash Ratio | 0.24 | 0.28 | 0.25 | 0.25 | 0.24 |
| Solvency Ratio | 0.06 | 0.05 | 0.05 | 0.07 | 0.07 |
| Operating Cash Flow Ratio | 0.05 | 0.05 | 0.04 | 0.04 | 0.06 |
| Short-Term Operating Cash Flow Coverage | 0.14 | 0.15 | 0.15 | 0.17 | 0.22 |
| Net Current Asset Value | $ 37.10B | $ 34.36B | $ 30.79B | $ 29.38B | $ 12.13B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.21 | 0.22 | 0.20 | 0.19 | 0.19 |
| Debt-to-Equity Ratio | 0.65 | 0.67 | 0.63 | 0.58 | 0.64 |
| Debt-to-Capital Ratio | 0.39 | 0.40 | 0.38 | 0.37 | 0.39 |
| Long-Term Debt-to-Capital Ratio | 0.05 | 0.10 | 0.08 | 0.09 | 0.13 |
| Financial Leverage Ratio | 3.07 | 3.09 | 3.09 | 2.95 | 3.31 |
| Debt Service Coverage Ratio | 0.25 | 0.25 | 0.24 | 0.36 | 0.36 |
| Interest Coverage Ratio | 5.90 | 5.01 | 4.61 | 5.34 | 5.40 |
| Debt to Market Cap | 1.27 | 1.06 | 1.08 | 0.85 | 0.87 |
| Interest Debt Per Share | 13.80 | 13.34 | 12.04 | 11.56 | 11.68 |
| Net Debt to EBITDA | 1.17 | 1.00 | 1.14 | 0.90 | 0.88 |
| Profitability Margins | |||||
| Gross Profit Margin | 10.73% | 11.13% | 11.88% | 13.14% | 13.23% |
| EBIT Margin | 4.06% | 3.50% | 3.35% | 4.41% | 3.90% |
| EBITDA Margin | 5.07% | 4.38% | 4.19% | 5.36% | 4.89% |
| Operating Profit Margin | 3.51% | 2.96% | 2.95% | 3.89% | 3.80% |
| Pretax Profit Margin | 3.46% | 2.91% | 2.71% | 3.80% | 3.77% |
| Net Profit Margin | 2.02% | 1.65% | 1.45% | 2.42% | 2.36% |
| Continuous Operations Profit Margin | 2.46% | 2.13% | 1.98% | 3.01% | 2.91% |
| Net Income Per EBT | 58.30% | 56.76% | 53.41% | 63.77% | 62.54% |
| EBT Per EBIT | 98.77% | 98.52% | 92.01% | 97.71% | 99.25% |
| Return on Assets (ROA) | 2.46% | 2.06% | 1.78% | 2.84% | 3.12% |
| Return on Equity (ROE) | 7.54% | 6.35% | 5.50% | 8.38% | 10.32% |
| Return on Capital Employed (ROCE) | 10.15% | 8.55% | 8.56% | 10.31% | 11.46% |
| Return on Invested Capital (ROIC) | 4.97% | 4.47% | 4.49% | 6.21% | 6.72% |
| Return on Tangible Assets | 2.70% | 2.23% | 1.94% | 3.12% | 3.49% |
| Earnings Yield | 15.10% | 10.37% | 9.84% | 14.07% | 14.89% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.19 | 3.23 | 3.37 | 3.19 | 3.40 |
| Payables Turnover | 4.12 | 4.11 | 4.20 | 3.91 | 4.46 |
| Inventory Turnover | 5.58 | 6.28 | 6.26 | 5.85 | 6.91 |
| Fixed Asset Turnover | 14.71 | 14.46 | 14.22 | 14.33 | 14.02 |
| Asset Turnover | 1.22 | 1.24 | 1.23 | 1.17 | 1.32 |
| Working Capital Turnover Ratio | 6.23 | 6.41 | 6.60 | 7.31 | 9.79 |
| Cash Conversion Cycle | 91.39 | 82.50 | 79.54 | 83.50 | 78.24 |
| Days of Sales Outstanding | 114.53 | 113.14 | 108.20 | 114.48 | 107.26 |
| Days of Inventory Outstanding | 65.40 | 58.11 | 58.28 | 62.42 | 52.82 |
| Days of Payables Outstanding | 88.53 | 88.76 | 86.94 | 93.41 | 81.85 |
| Operating Cycle | 179.92 | 171.25 | 166.48 | 176.91 | 160.09 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.66 | 1.57 | 1.41 | 1.36 | 1.78 |
| Free Cash Flow Per Share | 1.03 | 0.92 | 0.61 | 0.59 | 0.33 |
| Dividend Paid and CapEx Coverage Ratio | 1.20 | 0.97 | 0.75 | 0.82 | 0.74 |
| Capital Expenditure Coverage Ratio | 2.65 | 2.43 | 1.76 | 1.77 | 1.23 |
| Operating Cash Flow Coverage Ratio | 0.12 | 0.12 | 0.12 | 0.12 | 0.16 |
| Operating Cash Flow to Sales Ratio | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Free Cash Flow Yield | 10.10% | 7.80% | 5.90% | 5.16% | 2.76% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 6.64 | 9.64 | 10.16 | 7.11 | 6.72 |
| Price-to-Sales (P/S) Ratio | 0.13 | 0.16 | 0.15 | 0.17 | 0.16 |
| Price-to-Book (P/B) Ratio | 0.50 | 0.61 | 0.56 | 0.60 | 0.69 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.90 | 12.82 | 16.94 | 19.39 | 36.29 |
| Price-to-Operating Cash Flow Ratio | 6.16 | 7.54 | 7.32 | 8.42 | 6.76 |
| Price-to-Earnings Growth (PEG) Ratio | 0.26 | 0.47 | -0.28 | -0.71 | 0.51 |
| Enterprise Value Multiple | 3.80 | 4.64 | 4.65 | 4.11 | 4.12 |
| Enterprise Value | 54.66B | 55.96B | 50.68B | 51.08B | 43.51B |
| EV to EBITDA | 3.80 | 4.64 | 4.65 | 4.11 | 4.12 |
| EV to Sales | 0.19 | 0.20 | 0.19 | 0.22 | 0.20 |
| EV to Free Cash Flow | 14.28 | 16.33 | 22.42 | 24.81 | 46.16 |
| EV to Operating Cash Flow | 8.88 | 9.60 | 9.69 | 10.77 | 8.60 |
| Tangible Book Value Per Share | 18.41 | 18.02 | 16.91 | 17.25 | 14.61 |
| Shareholders’ Equity Per Share | 20.46 | 19.35 | 18.51 | 19.26 | 17.37 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.29 | 0.27 | 0.27 | 0.21 | 0.23 |
| Revenue Per Share | 76.47 | 74.30 | 70.33 | 66.61 | 75.94 |
| Net Income Per Share | 1.54 | 1.23 | 1.02 | 1.61 | 1.79 |
| Tax Burden | 0.58 | 0.57 | 0.53 | 0.64 | 0.63 |
| Interest Burden | 0.85 | 0.83 | 0.81 | 0.86 | 0.97 |
| Research & Development to Revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| SG&A to Revenue | 0.07 | 0.03 | 0.01 | 0.01 | 0.01 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.88 | 0.99 | 1.01 | 0.68 | 0.81 |
Currency in CNY